This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

July's Best ETFs: Pro-Biotech, or Anti-Commodity

In July, the best-performing exchange-traded funds bet either against commodities, or on biotechnology stocks.

With the sharp pullback in the price of oil to the $110 level from the $140 level, the UltraShort Oil & Gas ProShares (DUG) gained 32.24% in July. The fund tracks the inverse of the Dow Jones U.S. Oil & Gas Index with 200% leverage.

The second-best performer, iShares MSCI Turkey Investible Market Index Fund (TUR), added 25.23% for the month. This index fund, which began trading on March 28, is off to a good start.

Two other hot newcomers with even shorter track records focus on shorting commodities. For July, the PowerShares DB Commodity Double Short ETN (DEE) is up 23.06%. Over the same period, the PowerShares DB Agriculture Double Short ETN (AGA) returned 21.70%.

Most of the remaining funds on the list hold biotech stocks like Genetech (DNA), Amgen (AMGN - Get Report) and Biogen Idec (BIIB).

The best-performing of these biotechnology funds are the SPDR S&P Biotech ETF (XBI) and the Biotech HOLDRs Trust (BBH), appreciating 20.10% and 19.75%, respectively.

Climbing out of the abyss, the Regional Bank HOLDRs Trust (RKH) halved its loss over the last year with a solid, 16.60% performance in July. Top holdings include JPMorgan Chase (JPM), Wells Fargo (WFC) and Bank of America (BAC - Get Report).

Best Performing ETFs in July
Fund (Ticker) Rating 1 Month Total Return % 3 Month Total Return % Objective
ProShares Ultra Short Oil & Gas (DUG) E 32.24 13.27 Sector - Energy/Natural Res
iShares MSCI Turkey Inv Mkt Idx (TUR) U 25.23 6.45 Non-US Equity
PowerShares DB Commodity Double Sht (DEE) U 23.06 NA Growth - Domestic
PowerShares DB Agri Double Sht (AGA) U 21.70 NA Growth - Domestic
SPDR S&P Biotech ETF (XBI) B- 20.10 25.30 Sector - Health/Biotechnology
HOLDRS Biotech (BBH) C+ 19.75 26.56 Sector - Health/Biotechnology
First Trust AMEX Biotechnology (FBT) C- 17.29 15.57 Sector - Health/Biotechnology
HOLDRS Regional Bank (RKH) D+ 16.60 -14.22 Sector - Financial Services
iShares Nasdaq Biotechnology (IBB) C+ 15.70 14.80 Sector - Health/Biotechnology
PowerShares Dynamic Biotech&Genome (PBE) C- 15.65 12.13 Sector - Health/Biotechnology
Source: Ratings

For an explanation of our ratings, click here.
Kevin Baker became the senior financial analyst for TSC Ratings upon the August 2006 acquisition of Weiss Ratings by, covering mutual funds. He joined the Weiss Group in 1997 as a banking and brokerage analyst. In 1999, he created the Weiss Group's first ratings to gauge the level of risk in U.S. equities. Baker received a B.S. degree in management from Rensselaer Polytechnic Institute and an M.B.A. with a finance specialization from Nova Southeastern University.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
TUR $38.31 0.45%
DUG $59.13 -0.92%
AGA $30.50 1.67%
DEE $80.00 8.86%
AMGN $161.10 -1.48%


Chart of I:DJI
DOW 17,719.92 -78.57 -0.44%
S&P 500 2,080.41 -9.70 -0.46%
NASDAQ 5,108.6660 -18.8590 -0.37%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs